US Periodontal Therapeutics Market Analysis

US Periodontal Therapeutics Market Executive Summary

US Periodontal Therapeutics Market is at around $366.6 Mn in 2023 and is projected to reach $522.7 Mn in 2030, exhibiting a CAGR of 5.2% during the forecast period.

Periodontal disease, commonly known as gum disease, is a major dental health disease associated with inflammation and infection of the gums surrounding the teeth. Periodontitis is a very common condition, usually caused by poor oral hygiene, and can be prevented in most cases by surgical, non-surgical, or therapeutic treatment procedures Periodontal therapeutics include the use of antibiotics alone for the treatment of periodontitis and is relatively a small but lucrative method, gaining promise among patients and dentists. Metronidazole, amoxicillin, and doxycycline are often used antibiotics in periodontal therapy. Adjunctive therapies for reducing gingival inflammation and plaque include a variety of mouthwashes and rinses that contain antimicrobial agents such as hydrogen peroxide, chlorhexidine, and essential oils.

Periodontitis, a prevalent gum disease in the US, affects approximately 40% of adults aged 30 and older, with higher rates in men (50%) compared to women (33%). The prevalence increases significantly with age, impacting 60% of adults aged 65 and older. Demographic factors such as age, gender, socioeconomic status, and access to dental care play a crucial role in the incidence of periodontitis. Lower-income and education levels are associated with higher rates of the disease, reflecting disparities in oral healthcare access and awareness. The healthcare expenses related to periodontitis are substantial, contributing significantly to the overall dental care costs in the US.  The market, therefore, is driven by significant factors like Rise in prevalence of periodontitis, Emphasis on Preventive Oral Care, and Technological Developments. However, Stringent Regulatory Requirements, Side Effects, and Complications, High Cost restrict the growth and potential of the market.

Bausch Health Companies Inc. and its oral health care division, OraPharma announced plans to team up with the League of United Latin American Citizens (LULAC), the biggest Hispanic group in the US. Their goal is to spread awareness about gum disease among Hispanic communities. This collaboration aims to help Hispanics better understand how to detect and treat gum disease.

Market Dynamics

Market Growth Drivers

Rise in prevalence of periodontitis: Periodontitis affects approximately 40% of adults aged 30 and older, with higher rates in men (50%) compared to women (33%).  This leads to increased demand for treatments and products. Consequently, oral health awareness rises, resulting in more professional care visits. Additionally, persistent risk factors ensure ongoing market needs.

Emphasis on Preventive Oral Care: The future of periodontal care lies in precision prevention. Genetic testing will identify susceptibility to periodontal diseases. Biomarker analysis will enable ultra-early detection of inflammation. Personalized probiotics will optimize oral microbiomes. Nanotechnology-enhanced oral care products will provide targeted plaque control.

Technological Developments: Workflows in periodontal practices are streamlined by technological integration. Traditional molding procedures are eliminated by using digital impressions, which save time. Treatment planning is expedited with AI-assisted diagnosis. Dental doctors and team members can easily share data thanks to cloud-based technology. Online scheduling and automated appointment reminders enhance patient care.

Market Restraints

Stringent Regulatory Requirements: FDA rigorous approval process poses a substantial barrier to market entry for new periodontal treatments in the US. Additionally, varying state regulations and insurance coverage inconsistencies complicate nationwide adoption and reimbursement, deterring investment in advanced periodontal care technologies.

Side Effects and Complications: Potential side effects like post-operative pain and swelling can deter patients from seeking comprehensive periodontal care. These concerns arise particularly with invasive treatments such as periodontal surgery or dental implants, where discomfort and recovery time are significant considerations. Fear of pain and swelling may lead patients to delay or avoid necessary procedures, compromising their oral health and exacerbating existing periodontal conditions. However, advancements in minimally invasive techniques, improved anaesthesia, and post-operative care protocols aim to mitigate these side effects.

High cost: High costs, combined with socioeconomic disparities, result in delayed treatments and worsened oral health outcomes, particularly in low-income and uninsured populations. This financial barrier significantly impacts the growth of the periodontal market. Currently, approximately 40% of Americans face challenges in accessing comprehensive periodontal care due to financial constraints, underscoring the widespread impact of cost on oral health outcomes and market dynamics.

Regulatory Landscape and Reimbursement scenario

The regulatory landscape of the US dental periodontics market is governed by multiple entities, including the American Dental Association (ADA) and the American Academy of Periodontology (AAP), which set professional standards and guidelines. The Food and Drug Administration (FDA) oversees the approval and regulation of dental devices, materials, and drugs. State dental boards enforce licensure requirements, practice standards, and continuing education mandates for periodontists. The regulatory environment aims to ensure patient safety, high-quality care, and the ethical practice of periodontics.

In the US dental periodontics market, reimbursement plays a crucial role in shaping treatment patterns and patient access to care. Dental insurance policies often cover periodontal treatments such as scaling, root planning, and periodontal maintenance, though coverage specifics can vary widely. Reimbursement rates from insurance companies or government programs like Medicaid impact the financial viability of dental practices and influence the choice of treatment modalities recommended by periodontists. Providers navigate a landscape where balancing patient needs with financial considerations is essential, often requiring clear communication with patients regarding coverage limitations and out-of-pocket expenses for comprehensive periodontal care.

Competitive Landscape

Key Players

Here are some of the major key players in US Periodontal Therapeutics Market:

• Pfizer Inc.
• Lupin Ltd
• Teva Pharmaceuticals USA, Inc.
• Sun Pharmaceutical Industries Ltd.
• Tokyo Chemical Industry Co., Ltd.
• Bausch Health Companies Inc.
• Melinta Therapeutics LLC
• Cipla, Inc.
• Chartwell Pharmaceuticals LLC.
• ASA Dental S.p.A.
• Steris-Hu-Friedy
• Carl Martin GmBH